SCHEMBL7250606

SCHEMBL7250606

O=C(NC1CCCCC1)C(c1cccnc1)N(CCc1c[nH]c2ccccc12)C(=O)Cc1c[nH]c2ccccc12

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
ALDH1A1 P00352 3/20 0.45
MAPK1 P28482 1/20 0.45
MDM2 Q00987 1/20 0.45
MAPT P10636 2/20 0.44
HTT P42858 2/20 0.43
HPGD P15428 1/20 0.43
RECQL P46063 1/20 0.43
POLB P06746 1/20 0.43
MC4R P32245 1/20 0.43
MC5R P33032 1/20 0.43
MC3R P41968 1/20 0.43
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
TSHR P16473 1/20 0.42
KDM4E B2RXH2 1/20 0.42
LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7251520 0.80 KMT2A (0.46) MEN1KMT2ASMN1; SMN2ALDH1A1MAPK1
SCHEMBL9943392 0.79 HPGD (0.47) MEN1KMT2ASMN1; SMN2ALDH1A1MAPK1
SCHEMBL17956980 0.79 NPSR1 (0.53) MEN1KMT2ASMN1; SMN2ALDH1A1MAPK1
SCHEMBL9943325 0.78 HPGD (0.44) MEN1KMT2ASMN1; SMN2ALDH1A1MAPK1
SCHEMBL7253743 0.78 MC5R (0.44) MEN1KMT2ASMN1; SMN2ALDH1A1MAPK1
SCHEMBL23973931 0.77 YAP1 (0.55) SMN1; SMN2ALDH1A1MDM2MAPTTSHR
SCHEMBL17956969 0.75 KMT2A (0.51) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT
SCHEMBL9943348 0.75 HPGD (0.46) MEN1KMT2ASMN1; SMN2ALDH1A1MAPK1
SCHEMBL7256847 0.75 MC4R (0.43) MEN1KMT2ASMN1; SMN2ALDH1A1MAPK1
SCHEMBL25208378 0.75 YAP1 (0.71) MEN1KMT2ASMN1; SMN2ALDH1A1MDM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030195212-A1 Novel melanocortin receptor agonists and antagonists MELACURE THERAPEUTICS AB (SE) 2003-10-16 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195212-A1 Novel melanocortin receptor agonists and antagonists MC1R, MC5R, MC4R MEN1 1200/4885KMT2A 1399/4885SMN1; SMN2 4503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.